TARA vs UNH

Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, largely tied to the binary outcome of TARA-002. While the recent FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations reinforces its potential for market leadership and addresses a significant unmet medical need, recent financial updates temper enthusiasm. Q1 2026 saw a widen...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...